EUVIMEDSkopri EUVIMED
Multizentrische StudieOpen access · CC BY-NC 4.0

A Care Pathway for the Treatment of IBD Reduces Healthcare Costs and Is Cost‐Effective: Results of the Multicentre IBD Value Study

Elyke H Visser iD, Martijn A Oude Voshaar, Reinier C A van Linschoten, Alexander G L Bodelier, Claire Fitzpatrick, Vincent de Jonge, Hestia Vermeulen, K Evelyne Verweij, Sanne van der Wiel, Daniëlle van der Horst, C Janneke van der Woude, R L West and 1 more

Alimentary Pharmacology & Therapeutics · 2026-08 · 64 (3) · 313-325

DOI: 10.1111/apt.70690 ↗

At a glance

Multizentrische Studie in Alimentary Pharmacology & Therapeutics, published online on 2026-04-23. Written by Elyke H Visser and 12 co-authors. Institution: Department of Gastroenterology & Hepatology, Franciscus Hospital, Rotterdam, the Netherlands. Major MEDLINE topics: Inflammatory Bowel Diseases, Health Care Costs, Critical Pathways. Cited 2 times so far (Crossref); 54 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: AbbVie, Celltrion, Dr. Falk Pharma.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background

An advanced therapy care pathway (ACP) for the treatment of patients with IBD can reduce practice variation and improve outcomes.

Aims

This study aimed to estimate the effect of the ACP on costs and quality of life, and to assess the cost‐effectiveness of the ACP.

Methods

A cost‐utility and cost‐effectiveness analysis was conducted from a societal perspective. The ACP was implemented in six hospitals, and two hospitals in the same region served as controls. Costs and quality of life were assessed during a baseline period (December 2020–December 2021) and an intervention period after implementing the ACP (March 2022–March 2023). Quality‐adjusted life years (QALYs) were derived from the EQ‐5D‐5L; disease control from the IBD‐Control questionnaire. A difference‐in‐differences (DiD) analysis was conducted, and the net monetary benefit and incremental cost‐effectiveness ratio (ICER) were calculated.

Results

In total, 1,173 patients were included (intervention n = 841, control n = 332). Baseline costs per patient were €23,259.96 in the intervention hospitals and €22,837.93 in the control hospitals. During the intervention period, costs decreased to €20,959.76 in intervention hospitals. This reduction was not observed in control hospitals (€22,191.21). The DiD‐analysis showed cost savings of −€1933.69; QALYs (0.001) and disease control (0.15) did not change. The ICER indicated cost savings without compromising quality of life or disease control.

Conclusions

The implementation of an ACP for the treatment of patients with IBD reduces costs, maintains quality of life and disease control, and is cost‐effective. These results emphasise that the implementation of care pathways in current practices should be considered. Trial registration number: NL‐OMON21751. Website: Value‐based healthcare for Inflammatory Bowel Disease: Improving (cost‐) effectiveness.

Subjects

MeSH terms (MEDLINE)

Inflammatory Bowel DiseasesHealth Care CostsCritical PathwaysHumansCost-Benefit AnalysisFemaleCost-Effectiveness AnalysisQuality of LifeMaleQuality-Adjusted Life YearsMiddle AgedAdultAgedSurveys and Questionnaires

Author keywords

advanced therapiescare pathwaycost‐effectivenessinflammatory bowel diseasevalue‐based healthcare

Authors and institutions

  • Department of Gastroenterology & Hepatology, Franciscus Hospital, Rotterdam, the Netherlands.
  • Department of Gastroenterology & Hepatology, Erasmus MC, Rotterdam, the Netherlands.
  • Department of Public Health, Erasmus MC, Rotterdam, the Netherlands.
  • Department of General Practice, Erasmus MC, Rotterdam, the Netherlands.
  • Department of Gastroenterology & Hepatology, Amphia Hospital, Breda, the Netherlands.
  • Department of Gastroenterology & Hepatology, IJsselland Hospital, the Netherlands.

ORCID profiles: Elyke H Visser

Funding

  • AbbVie
  • Celltrion
  • Dr. Falk Pharma
  • Ferring
  • Janssen Pharmaceuticals
  • Eli Lilly and Company
  • Merck Sharp and Dohme
  • Pfizer

Cite

APA

Visser, E. H., Voshaar, M. A. O., van Linschoten, R. C. A., Bodelier, A. G. L., Fitzpatrick, C., de Jonge, V., Vermeulen, H., Verweij, K. E., van der Wiel, S., van der Horst, D., van der Woude, C. J., West, R. L., & van Noord, D. (2026). A Care Pathway for the Treatment of IBD Reduces Healthcare Costs and Is Cost‐Effective: Results of the Multicentre IBD Value Study. Alimentary Pharmacology & Therapeutics, 64(3), 313-325. https://doi.org/10.1111/apt.70690

Vancouver

Visser EH, Voshaar MAO, van Linschoten RCA, Bodelier AGL, Fitzpatrick C, de Jonge V, et al. A Care Pathway for the Treatment of IBD Reduces Healthcare Costs and Is Cost‐Effective: Results of the Multicentre IBD Value Study. Alimentary Pharmacology & Therapeutics. 2026;64(3):313-325. doi:10.1111/apt.70690

BibTeX
@article{Visser2026,
  author = {Visser, Elyke H and Voshaar, Martijn A Oude and van Linschoten, Reinier C A and Bodelier, Alexander G L and Fitzpatrick, Claire and de Jonge, Vincent and Vermeulen, Hestia and Verweij, K Evelyne and van der Wiel, Sanne and van der Horst, Daniëlle and van der Woude, C Janneke and West, R L and van Noord, D},
  title = {A Care Pathway for the Treatment of IBD Reduces Healthcare Costs and Is Cost‐Effective: Results of the Multicentre IBD Value Study},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  volume = {64},
  number = {3},
  pages = {313--325},
  doi = {10.1111/apt.70690}
}
Start for free →